Use of Affinity Allows Anti-Inflammatory and Anti-Microbial Dual Release that Matches Suture Wound Resolution.

Surgical sutures are vulnerable to bacterial infections and biofilm formation. At the suture site, pain and undesirable, excess inflammation are additionally detrimental to wound healing. The development of a polymerized cyclodextrin (pCD) coated surgical suture introduces the capability to locally deliver both anti-inflammatory and anti-microbial drugs throughout the phases of acute and chronic healing. Local delivery allows for the improvement of wound healing while reducing related systemic side effects and drug resistance. Through testing, it has been shown that the fabrication of our pCD coating minimally affects the suture's mechanical properties. In-vitro studies show measurable and consistent drug delivery for nearly five weeks. The therapeutic level of this delivery is sufficient to show inhibition of bacterial growth for four weeks, and free-radical scavenging (an in-vitro anti-inflammatory activity approximation) for two weeks. With this pCD coating technique, we maintain clinical performance standards while also introducing a long-term dual delivery system relevant to the wound healing timeframe. This article is protected by copyright. All rights reserved.